All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On October 16, 2020, KTE-X19 received positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
The autologous anti-CD19 CAR T-cell product, KTE-X19, is now recommended in Europe for the treatment of adults with R/R MCL who have received ≥ 2 lines of prior therapy including a Bruton’s tyrosine kinase inhibitor. It was in January 2020 that the Marketing Authorization Application for KTE-X19 was fully validated by the European Commission prior to evaluation by the EMA.
Promising results from the ongoing phase II ZUMA-2 trial (NCT02601313), evaluating the efficacy and safety of KTE-X19 in patients with R/R MCL, provided the foundations for these decisions. For the full study design and results presented at the 61st American Society of Hematology (ASH) meeting in Orlando, US, click here. The final efficacy and safety data were recently published in The New England Journal of Medicine, and are summarized by the Lymphoma Hub here.
KTE-X19 was also granted accelerated approval by the U.S. Food and Drug Administration (FDA) in July 2020, making it the first CAR T-cell therapy approved for the treatment of MCL.
This CHMP recommendation is currently under review by the European Commission and a decision regarding the marketing authorization of KTE-X19 is expected in the coming months.
Kite. European CHMP adopts positive opinion for Kite’s KTE-X19 for the treatment of relapsed or refractory mantle cell lymphoma. https://www.businesswire.com/news/home/20201016005357/en/European-CHMP-Adopts-Positive-Opinion-for-Kite%E2%80%99s-KTE-X19-for-the-Treatment-of-Relapsed-or-Refractory-Mantle-Cell-Lymphoma. Published Oct 16, 2020. Accessed Oct 16, 2020.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox